Genmab Is Said to Near Deal to Buy Cancer Drugmaker Merus
PositiveFinancial Markets

Genmab A/S, a leading Danish biotechnology company, is reportedly close to finalizing a deal to acquire Merus NV, a Dutch firm focused on developing innovative treatments for head and neck cancer. This acquisition could significantly enhance Genmab's portfolio and strengthen its position in the oncology market, which is crucial as the demand for effective cancer therapies continues to rise.
— Curated by the World Pulse Now AI Editorial System